Overcoming kinase resistance in chronic myeloid leukemia
Authors:
- Francis LeeFLFrancis Lee
- Abderrahim FandiAFAbderrahim Fandi
- Maurizio VoiMVMaurizio Voi
- 1 January 2008
- journal article
- review article
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 40 (3) , 334-343
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phaseBlood, 2007
- Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cellsBlood, 2007
- Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapyBlood, 2006
- Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph + leukemia in miceProceedings of the National Academy of Sciences, 2006
- AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid LeukemiaClinical Cancer Research, 2005
- Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pumpBlood, 2004
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemiasBlood, 2002
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Transformation of Myeloid Leukemia Cells to Cytokine Independence by Bcr-Abl Is Suppressed by Kinase-defective HckJournal of Biological Chemistry, 2000